How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

Aguirre-Boza, Francisca; P., Pamela San Martín; B, María Teresa Valenzuela

doi:10.1080/21645515.2021.1965424

Cited by 7 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The male-to-female ratio of reported AEFIs for DTaP, DTaP-Hib, and DTaP-IPV/Hib was 1.27:1, 1.05:1, and 0.95:1, respectively. The reporting rate of DTaP was higher than the levels reported in Chile ( 17 ), while the reporting rate of DTaP-IPV/Hib was lower than in other regions ( 28 ). The reporting rates of AEFIs for DTaP and DTaP-IPV/Hib were highest in the ≥18 months age group.…”

Section: Discussioncontrasting

confidence: 63%

“…A major challenge to the safety of the DTaP combination vaccine is that the vaccine needs to be administered in early infancy. To assess the safety and effective administration of vaccines, especially when new vaccines are introduced in any country, WHO recommends that countries should establish effective AEFI reporting programs ( 17 ). The AEFI surveillance are conducted by either applying a passive or active approach to monitor vaccine safety in various countries ( 22–24 ).…”

Section: Introductionmentioning

confidence: 99%

“…Vaccines are usually administered to healthy people, including entire birth cohorts of infants and in vast numbers. However, adverse events following immunization (AEFI) may occur in the recipient following the use of any vaccine, the most severe cases are extremely rare and are usually mild and self-limiting (15)(16)(17). Scientific studies demonstrated that strong antibody-based and cellular immunoprotective stimulation against each component of pertussis typically requires a combination of several adjuvants (18,19).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019–2022

Chen,

Zhang,

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe DTaP-Hib and DTaP-IPV/Hib combination vaccine can be used as a substitute for the diphtheria, tetanus, and acellular pertussis combined vaccine (DTaP). We aimed to evaluate the safety of multi-component vaccines containing DTaP by analyzing the reporting rates and characteristics of adverse events following immunization (AEFIs) in Linping District during the years 2019 to 2022.MethodsWe obtained data of AEFI and vaccination from the National AEFI Surveillance System of China and Zhejiang Municipal Immunization Information Management System, respectively, during 2019–2022 for a descriptive, epidemiological analysis.ResultsThe total number of AEFI reported following vaccinations with DTaP-containing combination vaccines was 802 in Linping District from 2019 to 2022. The overall reporting rates of AEFIs following DTaP, DTaP-Hib, and DTaP-IPV/Hib vaccinations were 445.72 (537 cases), 536.29 (45 cases), and 306.13 (220 cases) per 100,000 doses in Linping District from 2019 to 2022, respectively. Only one case of a serious AEFI following DTaP vaccination, with a reporting rate of 0.83 per 100,000 doses. The composition ratio of vaccine product-related reactions for DTaP, DTaP-Hib, and DTaP-IPV/Hib were 99.81, 97.78, and 100.00%, respectively. The composition ratio of coincidental events for DTaP and DTaP-Hib were 0.19 and 2.22%, respectively. The reporting rates of total AEFIs for DTaP-IPV/Hib were lower than for DTaP. The reporting rate of local induration for DTaP-Hib was lower than for DTaP, and the reporting rates of local redness & swelling and local induration for DTaP-IPV/Hib were both lower than for DTaP. DTaP-IPV/Hib had a higher proportion of AEFIs in first quarter compared to DTaP. The reporting rate after the second dose of DTaP-Hib was higher than that of DTaP, and the reporting rates of AEFIs after the first dose and third dose of DTaP-IPV/Hib were lower than DTaP.ConclusionThe reported AEFIs to multi-component vaccines containing DTaP components during 2019–2022 in Linping District were mainly mild vaccine reactions. DTaP-containing combination vaccines demonstrated a good safety profile.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019–2022

Chen,

Zhang,

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Twenty-three studies reported on 830,585,553 doses of COVID-19 vaccines, 3,23-44 3 studies reported on 154,220,042 doses of HPV vaccines, 6,45,46 5 studies on 513,115,509 doses of influenza vaccines, 25,47-50 2 studies on 4,952,349 doses of acellular pertussis vaccines, 51,52 3 studies on 1,386,209 doses of smallpox vaccines, 50,53,54 and 2 studies on 24,200,000 doses of mixed vaccines (epidemic cerebrospinal meningitis and pneumococcal conjugate vaccine). 55 In the 23 studies involving COVID-19 vaccination, 647,308,174 doses of mRNA vaccines and 183,238,205 doses of non-mRNA vaccines were administered.…”

Section: Resultsmentioning

confidence: 99%

Cardiac Arrhythmia after COVID-19 Vaccination versus Non–COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Shi

Tang

Xia

et al. 2022

Preprint

View full text Add to dashboard Cite

Aims: Cardiac arrhythmia is a rare complication after vaccination. Recently, reports of arrhythmia after COVID-19 vaccination have increased. Whether the risk for cardiac arrhythmia is higher with COVID-19 vaccines than with non-COVID-19 vaccines remains controversial. This meta-analysis explored the incidence of arrhythmia after COVID-19 vaccination and compared it with the incidence of arrhythmia after non-COVID-19 vaccination. Methods: We searched the MEDLINE, Scopus, Cochrane Library, and Embase databases for English-language studies reporting the incidence of arrhythmia (the primary endpoint) after vaccination from January 1, 1947 to October 28, 2022. Secondary endpoints included incidence of tachyarrhythmia and all-cause mortality. Subgroup analyses were conducted to evaluate the incidence of arrhythmia by age (children [<18 years] versus adults [≥18 years]), vaccine type (mRNA COVID-19 vaccine versus non-mRNA COVID-19 vaccine; individual non-COVID-19 vaccines versus COVID-19 vaccine), and COVID-19 vaccine dose (first versus second versus third). Random-effects meta-analyses were performed, and the intrastudy risk for bias and the certainty of evidence were evaluated. This study was registered with PROSPERO (CRD42022365912). Results: The overall incidence of arrhythmia from 36 studies (1,528,459,662 vaccine doses) was 291.8 (95% CI 111.6-762.7) cases per million doses. The incidence of arrhythmia was significantly higher after COVID-19 vaccination (2263.4 [875.4-5839.2] cases per million doses; 830,585,553 doses, 23 studies) than after non-COVID-19 vaccination (9.9 [1.3-75.5] cases per million doses; 697,874,109 doses, 14 studies; P<0.01). Compared with COVID-19 vaccines, the influenza, pertussis, human papillomavirus, and acellular pertussis vaccines were associated with a significantly lower incidence of arrhythmia. The incidence of tachyarrhythmia was significantly higher after COVID-19 vaccination (4367.5 [1535.2-12,360.8] cases per million doses; 1,208,656 doses, 15 studies) than after non-COVID-19 vaccination (25.8 [4.5-149.4] cases per million doses; 179,822,553 doses, 11 studies; P<0.01). Arrhythmia was also more frequent after the third dose of COVID-19 vaccine (19,064.3 [5775.5-61,051.2] cases per million doses; 7968 doses, 3 studies) than after the first dose (3450.9 [988.2-11,977.6] cases per million doses; 41,714,762 doses, 12 studies; P=0.05) or second dose (2262.5 [2205.9-2320.7] cases per million doses; 34,540,749 doses, 10 studies; P<0.01). All-cause mortality was comparable between the COVID-19 and non-COVID-19 vaccination groups. Conclusions: The overall risk for arrhythmia after COVID-19 vaccination was relatively low, although it was higher in COVID-19 vaccine recipients than in non-COVID-19 vaccine recipients. This increased risk should be evaluated along with other important factors, such as the incidence of local outbreaks and the risk for arrhythmia due to COVID infection itself, when weighing the safety and efficacy of COVID-19 vaccines.

show abstract

“…Many countries have switched from wP- to aP-containing vaccines due to the lower reactogenicity of the latter ( 17 ). Low reactogenicity (i.e.…”

Section: Benefits Of Introducing Hexavalent Acellular Pertussis–inact...mentioning

confidence: 99%

Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru

Torres-Martinez

Chaparro

Mariño

et al. 2023

Revista Panamericana De Salud Pública

View full text Add to dashboard Cite

The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines with more antigens remain apparent in parts of these countries, where vaccine-preventable diseases in infants continue to be a major problem. The challenges include the heterogeneity of vaccine coverage within each country and in neighboring countries, which can contribute to poor rates of vaccination coverage; the adverse impact of the inward migration of unvaccinated individuals, which has favored the re-emergence of vaccine-preventable diseases; vaccine shortages; and the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the associated shifts in health care resources. To improve the coverage of pediatric vaccines in Colombia and Peru, it will be necessary to ensure the widespread integration into vaccine schedules of combination vaccines containing diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b and hepatitis B antigens with a three-dose primary series delivered at 2, 4 and 6 months of age followed by a booster at 18 months of age. Such vaccines play important roles in preventing diphtheria, tetanus and pertussis; eradicating polio; and providing boosting against H. influenzae type b.

show abstract

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

Cited by 7 publications

References 14 publications

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019–2022

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019–2022

Cardiac Arrhythmia after COVID-19 Vaccination versus Non–COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru

Contact Info

Product

Resources

About